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Hormonalcontraception inwomenwith
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review
Johan Verhaeghe
Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven,
Leuven, Belgium
A B S T R A C T Objective The metabolic syndrome (MS) is a set of five cardiovascular and metabolic risk
factors: elevated waist circumference, fasting plasma glucose, triglycerides and blood pressure;
and reduced HDL-cholesterol. The prevalence of the MS is rising worldwide, and is linked
to two diagnoses in young women: polycystic ovary syndrome (PCOS) and gestational
diabetes mellitus (GDM).
Methods This narrative review focuses on hormonal contraceptive choices available for
women in Europe with features of the MS.
Results The levonorgestrel-intrauterine system and progestogen-only pills containing
desogestrel or levonorgestrel have no significant effects on MS parameters. Combined
oestrogen-progestogen methods do not appear to increase waist circumference or the
incidence of glucose intolerance in women with PCOS or a history of GDM; their effect on
HDL-cholesterol and triglycerides is comparable with that observed in women without the
MS, while the effect on blood pressure remains inconclusive. The etonogestrel implant does
not affect body weight, triglycerides and blood pressure but mildly reduces insulin sensitivity
and HDL-cholesterol in healthy women. Depot medroxyprogesterone acetate increases body
weight and truncal fat deposition, and lowers glucose tolerance in women with previous
GDM.
Conclusions Low-dose hormonal contraception is safe for many women with the MS, but
high-dose progestogens must be avoided.
K E Y W O R D S Blood pressure; Gestational diabetes mellitus; HDL-cholesterol; Insulin resistance; Obesity;
Polycystic ovary syndrome; Triglycerides; Waist circumference
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T H E M E T A B O L I C S Y N D R O M E I N
W O M E N
The metabolic syndrome (MS) is not a single-cause
multiple-trait disease, but a cluster of characteristics
indicative of increased cardiovascular and metabolic
risk. Reaven was the first to elaborate on several
clinical and biochemical signs apparently related to
insulin resistance1. His insights triggered an avalanche
of studies examining a ‘syndromatic’ construct of
metabolic risk factors, which by gradual consensus
became known as the MS. Several diabetes and
cardiovascular expert panels and societies have pro-
posed overlapping criteria for the MS between 1999
and 2005, yet a consensus is slowly emerging. The
latest set of criteria, a joint effort of several international
organisations2, is summarised in Table 1. The optimal
threshold for central fat accumulation, as estimated by
the waist circumference, is uncertain and ethnicity-
specific cut-off points have been proposed2.
Despite growing consensus on the five criteria, the
MS remains a highly controversial entity. A recent
WHO expert report concludes that the MS is useful as
an educational concept but not as a clinical tool3.
Many, including Reaven himself, have called for its
immediate demise4. The author disagrees. There is no
doubt that the MS offers little or no extra value to
clinicians caring for patients with established type 2
diabetes or coronary heart disease. However, the MS
is a premorbid condition3, an ‘anteroom’ for possible
future metabolic and cardiovascular derangement.
Surely, practitioners caring for young women should
do their utmost to advise them on how they might
avoid being led into the ‘clinical room’. The presence
of one metabolic risk factor should prompt a thorough
evaluation of other risk factors. Disappointingly, this is
not yet embedded in current clinical practice. Based
upon the individual metabolic signature, caregivers
should discuss lifestyle choices and address specific
issues such as contraception.
Two clinical entities in women of reproductive age
are highly associated with the MS: the polycystic ovary
syndrome (PCOS) and gestational diabetes mellitus
(GDM). The prevalence of the MS is around 40% in
American women with a diagnosis of PCOS5, at least
in those who present with hyperandrogenism6; in
Europe, the prevalence may be somewhat lower5.
Women with PCOS are at higher risk for glucose
intolerance and type 2 diabetes7 and probably cardio-
vascular disease as well5. The prevalence of the MS was
threefold higher in Danish women with a history of diet-
treated GDM than in age-matched controls8; including
insulin-treated GDM would result in an even higher
risk. After adjustment for body mass index (BMI), an
elevated pre-pregnancy waist circumference remained a
risk factor for GDM in a large USA cohort9. Thus,
central adipose tissue accumulation in young women is a
portent of metabolic and cardiovascular pathology.
The prevalence of GDM around the globe has
increased in recent decades10. The same may be true
for PCOS: for example, a recent Australian study
produced a prevalence estimate of more than 10%
among young women11. The rising tide of both
obesity and the MS is, at least in part, responsible for
this development. The present narrative review
examines the contraceptive options for women with
features of the MS, PCOS or a history of GDM. A
literature search was performed using the author’s
dedicated library, amplified by reference hand search.
References were selected on the basis of perceived
scientific relevance and a focus on hormonal contra-
ceptive methods currently available in Europe. Clearly,
none of the non-hormonal contraceptive methods has
any effect on cardiovascular and metabolic risk.
C O N T R A C E P T I V E C H O I C E S F O R
W O M E N W I T H C E N T R A L A D I P O S E
A C C U M U L A T I O N
The only method with a deleterious effect on
body weight and fat distribution is the depot
Table 1 Criteria for the clinical diagnosis of the metabolic
syndrome (MS) in women*
Measure Categorical cut-off points
Elevated waist circumference 80 or 88 cm**
Elevated triglycerides*** 150 mg/dl (1.7 mmol/l)
Reduced HDL-cholesterol*** 550 mg/dl (1.3 mmol/l)
Elevated blood pressure*** Systolic 130 and/or
diastolic 85 mm Hg
Elevated fasting glucose*** 100 mg/dl (5.6 mmol/l)
*Three or more abnormal results are necessary for a
diagnosis of the MS.
**The optimal waist circumference cut-off remains
uncertain and may be ethnicity-specific.
***Drug treatment aimed at reversing this particular
condition is an alternate indicator.
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medroxyprogesterone acetate (DMPA) injection
(150 mg i.m.). In a prospective study, 30 months of
DMPA use was accompanied by increases in both body
weight and fat mass of 6.1 kg on average, and a linear
increment over time in the ratio of central (trunk) over
peripheral (limbs) fat12. Women with a central adipose
distribution at baseline showed a greater DMPA-
induced trunk fat accumulation12. Visceral adiposity
aggravates insulin resistance in the liver through the
release and portal vein efflux of free fatty acids and other
adipose tissue secretory products (adipokines)13.
Weight gain was observed in the majority of South-
African overweight/obese adolescents on DMPA14. In
addition, a 3.6-fold higher weight gain rate was
documented in a cohort of generally overweight
postpartum Hispanic-American women with a history
of GDM who used DMPA compared with those
resorting to non-hormonal contraception15. Weight
gain also occurred with the lower-dosed DMPA
104 mg administered subcutaneously16. Several me-
chanisms may explain the DMPA-induced weight gain,
including increased appetite12.
The effect of the single-rod etonogestrel implant on
body weight is uncertain, but a sustained weight
increment of more than 2 kg in comparison with
untreated women can probably be excluded17.
Progestogen-only pills (POPs) containing either
desogestrel 0.075 mg or levonorgestrel 0.03 mg, do
not appear to influence body weight18.
Regarding combined oral contraceptives (COCs),
a meta-analysis concluded that the available evidence
on weight change is insufficient; while some studies
reported a weight gain of up to 1.8 kg after 12
cycles, a large effect can be excluded19. Small
increases in fat mass or body water (51 kg) were
documented after six cycles in some studies20,21 but
again, the changes appear clinically insignificant for
COCs, the combination patch and the vaginal ring.
In overweight or obese women with PCOS (mean
baseline BMI 29.2–37.8 kg/m2), COCs did not
influence BMI or waist circumference after six
cycles22–25. In the study of women with previous
GDM already mentioned, weight gain rate among
COC users was comparable to that among non-
hormonal contraception users15.
Obesity affects the pharmacokinetics of drugs,
leading to a doubling of the interval needed to reach
steady-state levels of some COC compounds26.
Hence, there is a greater likelihood for ‘escape’ FSH
and LH pulsatile activity, follicle growth and ovulation
in obese users of COCs26 or a combination vaginal
ring27. It remains unclear whether obese women using
combination methods are at higher risk for method
failure28 but one clinical trial reported a greater than
expected incidence of pregnancies with the combined
patch in women whose weight exceeded 90 kg29. A
shortened pill-free interval (four days instead of the
conventional seven) ameliorated ovarian suppres-
sion30, and might be particularly helpful in obese
women. When starting hormonal contraceptives,
obese women should use back-up contraception in
the first 7–10 days (10 days being the mean
interval needed to reach progestogen steady-state
concentrations26).
There is no consensus at present with regard to
whether the risk of venous thromboembolism in
COC users is BMI-dependent, since five studies
examining this issue have produced inconsistent
results31. Until more data become available, obese
women should remain eligible for combination
methods, regardless of their BMI or fat distribution
(WHO category 2)31.
C O N T R A C E P T I V E C H O I C E S F O R
W O M E N W I T H G L Y C A E M I C
A B N O R M A L I T I E S
Progesterone and progestogens reduce tissue insulin
sensitivity, thereby leading to a compensatory increase
in insulin release following a glucose load. The
magnitude of the effect is dose-dependent and may
be compound-specific32,33. In women with the MS,
the combination of baseline insulin resistance and
progestogen use might accelerate the development of
impaired glucose tolerance/postprandial hyperglycae-
mia34. There is no evidence that ethinylestradiol
worsens insulin sensitivity35; in fact, oestrogen therapy
appears to improve insulin sensitivity in oestrogen-
deficient individuals36,37.
Table 2 summarises the methodology to evaluate
glucose metabolism in humans. The most frequently
used methods by far are fasting blood samples and
the oral glucose tolerance test (OGTT), from which
numerous insulin sensitivity and secretion indices
have been derived. Although several of these indices
have been reasonably well validated against
the hyperinsulinaemic euglycaemic clamp, the
Contraception and the metabolic syndrome Verhaeghe
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gold-standard method, their limitations should be
kept in mind38.
Use of DMPA in postpartum women with previous
GDM was associated with an early (within one to two
years) rise in the incidence of type 2 diabetes,
compared with COC use; the risk was about four-
fold higher in women with baseline triglycerides
4150 mg/dl39. These findings were replicated in
another USA cohort40.
Lower-dose progestogen-only methods have milder
or no effects. Although the etonogestrel implant
reduced insulin sensitivity by about 30% in healthy
women, as measured by the frequently-sampled
intravenous (i.v.) glucose tolerance test41, preliminary
data in diabetic women indicated no change in
HbA1C levels within two years of use
42. POPs
containing desogestrel or levonorgestrel had no
meaningful effect on OGTT parameters and HbA1C
levels in healthy women43. Compared with copper
intrauterine devices, the levonorgestrel-intrauterine
system (LNG-IUS) did not affect fasting glucose or
HbA1C levels over a one-year period in women with
type 1 diabetes44.
Low-dose COCs variably affected insulin sensitivity
in healthy women45, while the vaginal ring showed
minimal or no effect on insulin sensitivity46,47. A
meta-analysis of clinical trials with OGTT data
concluded that COCs as a class have no consistent
and relevant effect on glucose metabolism in women
without diabetes48. In addition, there was no evidence
of a meaningful difference between the available low-
dose COC preparations48.
In women with PCOS, the reported effects of
COCs during 3–12 cycles are largely reassuring,
showing no effect on insulin sensitivity assessed by
the euglycaemic clamp22,49,50, frequently-sampled i.v.
glucose tolerance test51, OGTT24,52, insulin tolerance
test53, or a fasting blood sample54,55, independent of
baseline BMI. Neither was there an effect on the
incidence of glucose intolerance24. However, in some
studies, a slight deterioration in insulin sensitivity was
observed with at least one COC preparation51,56,57. In
comparative trials examining the impact of two COCs,
the lower-dose preparation had more favourable
effects23,56.
Use of COCs in women with a history of GDM did
not appear to accelerate the recurrence of glucose
intolerance or diabetes15,39.
C O N T R A C E P T I V E C H O I C E S F O R
W O M E N W I T H
H Y P E R T R I G L Y C E R I D A E M I A O R
L O W H D L – C H O L E S T E R O L
The generally held view is that ethinylestradiol
increases triglyceride levels dose-dependently, whereas
the progestogen may reduce HDL-cholesterol de-
pending on dose and androgenic properties. The
impact of these changes on the development of
atherosclerosis remains unknown.
A rise in plasma triglycerides has been observed
consistently in healthy women using low-dose
COCs58–60, the patch61 and the ring62. The
magnitude of change varied considerably between
studies but was within the twofold range; the ring
produced a slightly higher increase than a levonor-
gestrel-containing COC in one study62. In over-
weight/obese women with PCOS, either no
significant change in triglycerides24,25,54,55 or an
increment within the twofold range53,63 was docu-
mented during COC use; in women with a history
of GDM, there was no COC-induced change in
plasma triglycerides64,65. The data show that there is
no amplified triglyceride response to COCs in
women with PCOS or previous GDM; in fact, the
response may be attenuated in those with higher
baseline levels64,65. Progestogen-only methods,
namely, the LNG-IUS66, the etonogestrel im-
plant67,68, and desogestrel- or levonorgestrel-
containing POPs69, do not raise plasma triglycerides.
The changes in HDL-cholesterol induced by hormo-
nal contraceptives are small. The etonogestrel implant
and levonorgestrel-containing COCs caused a 10–
20% reduction in HDL-cholesterol in healthy wo-
men62,67,68. On the other hand, the LNG-IUS66,
desogestrel- or levonorgestrel-containing POPs69, the
combined patch61 and ring62, and COCs containing
desogestrel58 or drospirenone60 were associated with
stable or up to 20% increased levels. In women with
PCOS, increased HDL-cholesterol levels during COC
use were reported consistently24,25,50,52–55,57,63. In
women with a history of GDM, the HDL-cholesterol
levels were also higher in COC users than in those
using non-hormonal methods15.
In sum, there is no evidence that hormonal
contraceptives have a more deleterious effect on
triglycerides and HDL-cholesterol levels in women
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with PCOS or a history of GDM than in healthy
women.
C O N T R A C E P T I V E C H O I C E S F O R
W O M E N W I T H H Y P E R T E N S I O N
Low-dose COCs produced a very small (51 mm Hg)
and reversible increase in mean systolic and diastolic
blood pressure in unselected populations. In a large
USA cohort, COC use doubled the relative risk of a
diagnosis of hypertension within four years, corre-
sponding to four diagnoses per 1,000 woman-years
attributable to OC use70. Thus, the overwhelming
majority of normotensive women who take COCs
remain normotensive.
In women with established hypertension, two
studies reported a further increase in blood pressure,
but the available evidence was deemed of low quality71.
Hypertension and COC use may also act synergistically
to increase the risk of myocardial infarction and stroke
but, again, the evidence is inconclusive, and the
estimated incidence of cardiovascular events is low
even in hypertensive women who take COCs (three
events per 10,000 woman-years between 20–40 years
of age)71. Drospirenone is a progestogen with anti-
mineralocorticoid and therefore mildly antihyper-
tensive properties72 (1 mg drospirenone 8 mg
spironolactone). A small trial showed a slight drop in
blood pressure (1–4 mm Hg) with drospirenone-
containing COCs73. There is a pressing need for
clinical trials that examine the blood pressure effects of
different COC preparations in healthy women and in
women with PCOS, previous GDM, or the MS. Until
more data become available, a diagnosis of severe
hypertension based upon correct and repeated mea-
surements (systolic 4160 and diastolic 4100 mm
Hg), is a contraindication (WHO category 4) for any
combined COC, patch or ring; mild hypertension
(systolic 140–159 and diastolic 90–99 mm Hg) is a
relative contraindication (WHO category 3)74.
The etonogestrel implant75 and POPs available in
Europe18 did not affect blood pressure in healthy
users. Neither did DMPA influence blood pressure in
women with a history of GDM15.
G E N E R A L R E C O M M E N D A T I O N S
Features of the MS are common in adolescent and
adult women in 2010. There are no studies on the
effect of hormonal contraceptives in women with
predefined MS. Yet a fair amount of data is available
from two populations with a considerably higher
prevalence of MS, namely, women with either PCOS
or a history of GDM.
Oestrogens and progestogens have the biological
potential to influence body weight and fat distribution,
insulin sensitivity and glucose tolerance, plasma lipids,
and blood pressure. Non-hormonal methods should
therefore remain the first-line contraceptive choice in
women with features of the MS. However, the LNG-
IUS and low-dose POPs have no meaningful meta-
bolic and blood pressure effects. Hence, clinicians and
women contemplating either one of these methods on
the basis of sound judgement, should not be denied this
choice because of the presence of features of the MS.
But low-dose combined methods are not necessa-
rily contra-indicated in metabolically-challenged wo-
men. With COCs or the vaginal ring, there is no solid
evidence of a heightened risk of central fat accumula-
tion, glucose intolerance or lipid profile deterioration
in women with PCOS or a history of GDM.
Nonetheless, women with baseline hypertriglyceri-
daemia should be observed closely for deterioration of
glucose tolerance and the lipid profile. In addition,
currently accepted contra-indications including hy-
pertension should be taken into account. To improve
the efficacy of low-dose combined methods, a short or
no hormone-free interval may be preferable, but more
data are needed in this regard. Back-up condom use
(the ‘double Dutch’) may also be recommended.
The jury is still out on the overall metabolic impact
of the etonogestrel implant: more studies are needed
with regard to the effects this contraceptive may have
on glucose tolerance and HDL-cholesterol in women
with features of the MS. But DMPA use should be
discouraged in women with the MS, because of its
deleterious effects on weight gain, fat distribution and
glucose tolerance. Systematic reviews are mandatory
to corroborate the present recommendations based on
the author’s overview of the literature.
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